Digoxin-like immunoreactive substance in postmortem blood of infants and children

A digoxin-like immunoreactive substance (DLIS) has been reported in the serum of infants not receiving digoxin. This study was undertaken to determine if DLIS is present in the postmortem blood and tissues of infants or children and whether the endogenous substance could interfere with forensic toxicological analysis in suspected overdose. Ninety blood specimens taken from the heart at autopsy of children or infants were screened for DLIS using commercial radioimmunoassay kits. The average age at death in these cases was 8.6 months, the median age was 2 months. DLIS equivalent to 0.25 to 2.0 ng/mL digoxin was found in one third of the cases. The incidence of positive findings was 5/6 stillborns, 10/45 Sudden Infant Death Syndrome (SIDS), 10/15 deaths as a result of infection, 4/7 homicides, 1/8 deaths caused by congenital defects, and 0/9 accidental deaths. The body distribution of DLIS was investigated and highest levels were found in the liver. Findings of DLIS in blood were correlated with renal failure, (elevated vitreous urea nitrogen), electrolyte imbalance, and liver trauma. Apparent concentrations were in the equivalent therapeutic range of digoxin and would not be confused with accidental or intentional overdose with digoxin.     

The contractual alternative to patents

A patent grants the holder a monopoly over the use of the patented invention for a specified time period. Although economists are generally opposed to monopoly, there seems to be a general consensus that the patent system is desirable.¹ The rationale for the patent system is that without ownership rights in inventions, there would not be optimal allocation of resources to inventive activities, just as with any other valuable resource over which there are not well-defined property rights. However, the patent system, since it confers monopoly rights, has its drawbacks as well. If independent parties are working simultaneously toward an invention, the first to produce the invention will receive a monopoly over its use, even though others may have been only a month behind. This may encourage inventors to work too intensively toward a patent, and could also have the effect of producing monopoly in a market that was characterized by competition before the patent was issued. In addition, competitors have an incentive to develop substitute processes to avoid infringement of the patent, when the use of the patented process would be more economical. A substitute for patents which provides ownership rights in an invention without governmental grant of a monopoly is the trade secret. The purpose of this paper is to introduce and develop the idea of the law of trade secrets as a contractual alternative to patents.